Wolverine Stack and the GLOW blend: what the third component changes

Two recovery-oriented formulations get compared constantly, usually on the wrong axis. The Wolverine Stack is BPC-157 and TB-500. The GLOW blend is those two plus GHK-Cu. Everything that follows from the comparison follows from that one difference.

One thing first. The Wolverine Stack is in this catalogue; GLOW is not. This is reading about how the two formulations are put together, not a choice between two things on the shelf here. The stocked formulation containing GHK-Cu is the four-component KLOW blend.

The compositions, side by side

Those are statements about what is in each vial. They are not instructions about anything.

Why the total milligram figure misleads

The common mistake is reading across the 'total peptide' row. Seventy milligrams against ten looks like a seven-fold difference in material, and it is not a difference in anything meaningful: five-sevenths of GLOW's mass is GHK-Cu. A GLOW vial holds 10 mg of BPC-157 and a Wolverine vial 5 mg — two-fold, not seven-fold. Same for TB-500.

Any per-milligram figure spanning the two has the same defect. Dividing anything by 70 mg when 50 mg of it is a different compound produces a number with no interpretation. Compare components to components, and look at the product pages for current prices.

BPC-157 — in both, and the weakest-sourced of the three

BPC-157 is a fifteen–amino acid sequence derived from a protein in human gastric juice. The thread that runs through its literature is angiogenesis — the growth of new blood vessels — with work pointing at VEGF receptor signalling and the nitric oxide pathway. Sikiric and colleagues' review covers the gastrointestinal programme the compound came out of (PMID 21548867).

Two caveats apply wherever it appears. Almost the whole literature traces to one group at the University of Zagreb, so independent replication is sparse; the partial exception in connective tissue is Chang and colleagues in Taiwan, who examined tendon cell outgrowth, survival and migration in culture alongside a rat model and reported effects on all three (PMID 21030672). And no receptor has been identified, which is a substantial gap in anything calling itself a mechanism. It is also on the World Anti-Doping Agency's prohibited list.

Evidence stage: rodent models with supporting cell culture. An early-phase clinical programme under the code PL 14736 examined inflammatory bowel disease and did not reach approval. The connective-tissue work is rat tendon, ligament and tendon-to-bone models, followed over days to weeks.

TB-500 — in both, and a fragment of what the papers studied

TB-500 is a short synthetic fragment of thymosin beta-4, the actin-sequestering protein. Goldstein, Hannappel and Kleinman's review is the standard account of how Tβ4 came to be examined in tissue repair (PMID 16099219). The mechanism at issue is cell migration: fibroblasts, endothelial cells and immune cells physically reaching an injury, which in poorly vascularised tissue is often what limits repair.

Read it with the molecule in mind: nearly all of it is on full-length Tβ4, not the fragment. The fragment carries the actin-binding region, which is why it was chosen, but a paper about Tβ4 is evidence about Tβ4. Full-length Tβ4 has been into early clinical trials; none produced an approval. See TB-500 for Tendon and Ligament Research.

Evidence stage: cell culture and animal models, with the clinical history belonging to the full-length protein.

GHK-Cu — the only real difference between the two

GHK-Cu is a copper-bound tripeptide, and it is what makes GLOW a different formulation rather than a larger one. Its literature is the oldest and largest of the three. Pickart and Margolina's review is the usual entry point (PMID 29986520), surveying gene-expression work in cultured human fibroblasts — GHK-Cu altering expression across a large number of genes, collagen genes among them — along with collagen synthesis in culture and animal wound models.

Two things to carry alongside it. That review is by the compound's discoverer, who has a long commercial association with it — worth knowing in the same way it is worth knowing that one laboratory produced most of the BPC-157 literature. And the copper is load-bearing rather than decorative: copper-dependent enzymes are part of the proposed mechanism, so GHK and GHK-Cu are not interchangeable despite the names.

Evidence stage: cell culture and animal models, with cosmetic-grade human skin work. Not an approved drug anywhere. For the chemistry, see Copper Peptides Explained; for the follicle literature, GHK-Cu for Hair Research.

How the difference actually bears on a research question

The honest framing is narrow. Adding GHK-Cu adds a literature about gene expression, collagen and skin. It does not deepen the evidence for the other two compounds, nor make the formulation more established.

Where the two-component version is the cleaner instrument. For a question about angiogenesis and cell migration — tendon, ligament, enthesis — GHK-Cu is a third variable with its own gene-expression and inflammatory effects, and anything observed with it present cannot be cleanly attributed. Fewer compounds, fewer confounds.

Where the third component is the point. For skin, photoageing, wound or follicle questions, GHK-Cu has the most published groundwork and the other two are the supporting pair. See What Is the GLOW Blend? and Inside the GLOW Blend.

Where neither is the answer. If the question is which single compound produced an effect, no blend can answer it. Single vials are the right tool; blends exist because one reconstitution and a fixed ratio are more convenient than three of each.

Where the evidence stops, for both

This matters more than the comparison does.

No combination has been studied as a combination. There is no published trial or animal study of BPC-157 plus TB-500, nor of the three-component mixture. The table above is a rationale assembled from three separate literatures, not evidence about either formulation. Descriptions of a blend 'replicating established protocols' overstate what exists — the ratios are conventions, not findings.

Combining compounds multiplies the unknowns rather than the evidence. Each of the three is unapproved, and two or three in a vial adds an interaction profile nobody has characterised. A blend of unapproved compounds is less well described than any one of its parts, not better.

All of it is animal and cell work. No controlled human trial has examined any of these three compounds for tendon, ligament, skin or recovery outcomes.

None of them is an approved drug in Canada. Not by Health Canada, not by the FDA, not by the EMA. In 2023 the FDA placed BPC-157 among the bulk substances it considers to carry significant risks for pharmacy compounding, which is a formal statement that the agency does not regard it as established.

For the two-component ratio in detail, see The Wolverine Stack 1:1 Ratio; for the four-component extension, What Is the KLOW Blend? and GLOW vs KLOW; for the general case, When Do You Actually Need a Peptide Blend?. Nothing here is medical, dosing or therapeutic guidance.

The Wolverine Stack is supplied here as 5 mg BPC-157 and 5 mg TB-500 in one vial. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. For laboratory research use only.

Common questions

What is the actual difference between the two? One component. Both contain BPC-157 and TB-500; GLOW adds 50 mg of GHK-Cu and its gene-expression and collagen literature. The shared components differ in quantity too — 5 mg each in the Wolverine Stack, 10 mg each in GLOW — so the seven-fold gap in totals is almost entirely the GHK-Cu.

Which one is better for tendon research? The two-component formulation is the cleaner instrument, because GHK-Cu would be a third uncontrolled variable. That is an argument about experimental design, not about efficacy — neither has been studied in a human.

Can I buy the GLOW blend here? No. It is not in this catalogue — it is described here because the comparison is the clearest way to explain what GHK-Cu adds to a formulation. The stocked formulation containing GHK-Cu is the KLOW blend, which is GLOW's three components plus KPV.

Is either combination approved or proven? Neither. No combination of these compounds has been studied as a combination, and none of the three is an approved drug in Canada. They are sold as research material for laboratory use only.

Selected Research References

1. Sikiric P, Seiwerth S, Rucman R, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design. 2011;17(16):1612-1632. pubmed.ncbi.nlm.nih.gov/21548867
2. Goldstein AL, Hannappel E, Kleinman HK. Thymosin Beta-4: Actin-Sequestering Protein Moonlights to Repair Injured Tissues. Trends in Molecular Medicine. 2005;11(9):421-429. pubmed.ncbi.nlm.nih.gov/16099219
3. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. International Journal of Molecular Sciences. 2018;19(7):1987. pubmed.ncbi.nlm.nih.gov/29986520
4. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The Promoting Effect of Pentadecapeptide BPC 157 on Tendon Healing Involves Tendon Outgrowth, Cell Survival, and Cell Migration. Journal of Applied Physiology. 2011;110(3):774-780. pubmed.ncbi.nlm.nih.gov/21030672

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.